The reassuring outcome of anti-FGFR inhibitors in different preclinical studies strengthened the rationale to employ FGFR tyrosine kinase inhibitors in GBM patients harboring the FGFR3-TACC3 fusion gene (11, 18). This evidence concerns the gene FGFR3 and glioblastoma.